| Schedule of Segment Information |
Segment
information for the three months ended September 30, 2026 is presented below:
Schedule of Segment Information
| | |
Pharmaceutical
Operations | | |
Premium
Nutritional Supplements | | |
Total
Reportable Segments | | |
Corporate
/ Other | | |
Total | |
| Revenue | |
| - | | |
| 13,942 | | |
| 13,942 | | |
| - | | |
| 13,942 | |
| Cost of goods sold | |
| - | | |
| 4,334 | | |
| 4,334 | | |
| - | | |
| 4,334 | |
| Research and development | |
| 3,892,387 | | |
| - | | |
| 3,892,387 | | |
| - | | |
| 3,892,387 | |
| General and administrative | |
| 260,685 | | |
| 245,753 | | |
| 506,438 | | |
| 1,406,489 | | |
| 1,912,927 | |
| Segment operating loss | |
| (4,153,072 | ) | |
| (236,145 | ) | |
| (4,389,217 | ) | |
| (1,406,489 | ) | |
| (5,795,706 | ) |
| Net loss | |
| (4,153,072 | ) | |
| (236,145 | ) | |
| (4,389,217 | ) | |
| (2,834,853 | ) | |
| (7,224,070 | ) |
Segment
information for the nine months ended September 30, 2026 is presented below:
| | |
Pharmaceutical
Operations | | |
Premium
Nutritional Supplements | | |
Total
Reportable Segments | | |
Corporate
/ Other | | |
Total | |
| Revenue | |
| - | | |
| 56,839 | | |
| 56,839 | | |
| - | | |
| 56,839 | |
| Cost of goods sold | |
| - | | |
| 11,877 | | |
| 11,877 | | |
| - | | |
| 11,877 | |
| Research and development | |
| 4,903,789 | | |
| - | | |
| 4,903,789 | | |
| - | | |
| 4,903,789 | |
| General and administrative | |
| 966,216 | | |
| 1,102,279 | | |
| 2,068,495 | | |
| 3,574,329 | | |
| 5,642,824 | |
| Segment operating loss | |
| (5,870,005 | ) | |
| (1,057,317 | ) | |
| (6,927,322 | ) | |
| (3,574,329 | ) | |
| (10,501,651 | ) |
| Other income (expense),
net | |
| - | | |
| - | | |
| - | | |
| (1,058,774 | ) | |
| (1,058,774 | ) |
| Net loss | |
| (5,870,005 | ) | |
| (1,057,317 | ) | |
| (6,927,322 | ) | |
| (4,633,103 | ) | |
| (11,560,425 | ) |
|